Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elona Biçaku
Observed names:
E Bicaku,
E. Bicaku,
E. Biçaku,
ELONA BICAKU,
Elona Bicaku,
Elona Biçaku
show all 6
Institution:
Moffitt Cancer Center
Observed institutions:
University of Pittsburgh,
Duke University,
University of South Florida,
Moffitt Cancer Center,
James A. Haley Veterans' Hospital,
Zhejiang Cancer Hospital,
BioNumerik (United States),
Hangzhou Dianzi University
show all 8
OpenAlex ID:
A5064405251
Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins
2005
·
Douglas C. Marchion
, Elona Bicaku
, et al.
·
Cancer Research
·
237
PDF
Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study
2007
·
Pamela Münster
, Douglas Marchion
, et al.
·
Journal of Clinical Oncology
·
232
PDF
Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
2004
·
Douglas C. Marchion
, Elona Bicaku
, et al.
·
Journal of Cellular Biochemistry
·
193
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
2009
·
Pamela Munster
, Douglas Marchion
, et al.
·
Clinical Cancer Research
·
160
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
2011
·
Scott Thomas
, Kenneth T. Thurn
, et al.
·
Breast Cancer Research and Treatment
·
122
BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
2011
·
Douglas C. Marchion
, Hope M. Cottrill
, et al.
·
Clinical Cancer Research
·
105
PDF
Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor–Mediated Signaling
2008
·
Elona Biçaku
, Douglas C. Marchion
, et al.
·
Cancer Research
·
98
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
2009
·
Adil I. Daud
, Jana Dawson
, et al.
·
Clinical Cancer Research
·
90
PDF
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
2005
·
Douglas C. Marchion
, Elona Bicaku
, et al.
·
Molecular Cancer Therapeutics
·
83
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
2009
·
Douglas C. Marchion
, Elona Bicaku
, et al.
·
Molecular Cancer Therapeutics
·
73
Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ
2005
·
Douglas C. Marchion
, Elona Bicaku
, et al.
·
Clinical Cancer Research
·
59
BAD-mediated apoptotic pathway is associated with human cancer development
2015
·
XIAOMANG B STICKLES
, DOUGLAS C MARCHION
, et al.
·
International Journal of Molecular Medicine
·
53
PDF
Human glioma PKC‐ι and PKC‐βII phosphorylate cyclin‐dependent kinase activating kinase during the cell cycle
2002
·
M. Acevedo‐Duncan
, R. Patel
, et al.
·
Cell Proliferation
·
50
PDF
In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
2012
·
E Bicaku
, Y Xiong
, et al.
·
British Journal of Cancer
·
44
PDF
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
2013
·
DOUGLAS C. MARCHION
, ELONA BICAKU
, et al.
·
Oncology Reports
·
26
PDF
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin
2012
·
Nisha Bansal
, Douglas C. Marchion
, et al.
·
Journal of Gynecologic Oncology
·
26
PDF
The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin
2011
·
Hye Sook Chon
, Douglas C. Marchion
, et al.
·
Gynecologic Oncology
·
25
Characterizing the Efficacy of Fermented Wheat Germ Extract Against Ovarian Cancer and Defining the Genomic Basis of Its Activity
2012
·
Patricia L. Judson
, Entidhar Al Sawah
, et al.
·
International Journal of Gynecological Cancer
·
24
Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy
2008
·
P. N. Munster
, M. Lacevic
, et al.
·
Journal of Clinical Oncology
·
16
Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-ι in human glioma cells
2005
·
Elona Bicaku
, Rekha Patel
, et al.
·
Tissue and Cell
·
16
Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies
2007
·
A. Daud
, M. Schmitt
, et al.
·
Journal of Clinical Oncology
·
10
Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: A clinical and translational Study
2005
·
P. N. Munster
, D. C. Marchion
, et al.
·
Journal of Clinical Oncology
·
9
Phase I trial of a sequence-specific combination of the HDAC inhibitor, valproic acid (VPA), and the topoisomerase II inhibitor, epirubicin, in advanced solid tumors: Clinical results and correlative studies
2006
·
P. N. Munster
, D. C. Marchion
, et al.
·
Journal of Clinical Oncology
·
6
Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer
2007
·
P. N. Munster
, D. C. Marchion
, et al.
·
Journal of Clinical Oncology
·
5
Ultrastructural study of protein kinase C-βII localization during the cell cycle of human glioma cells
2001
·
E. Biçaku
, M. Acevedo-Duncan
·
Tissue and Cell
·
3
Show more works
View as search
Works count:
46
Citation count:
1,771
H-index:
18
I10-index:
21
Year
Topic
Type